| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Gomisin J targets multiple pathways. It activates AMPK and LKB1, and inhibits lipogenic and lipolytic enzymes and inflammatory molecules, thereby suppressing lipid accumulation. It also inhibits HIV-1 replication. Its anti-cancer activity involves a multi-faceted mechanism. It is a substrate of CYP3A4, which is important for its metabolism.
|
|---|---|
| ln Vitro |
In vitro, Gomisin J inhibits HIV-1 IIIB replication in H9 T cells with an EC₅₀ of 1.5 µg/mL. It has anti-cancer effects and modulates lipid accumulation by regulating the expression of lipogenic and lipolytic enzymes. It activates AMPK and LKB1 in HepG2 cells.
|
| ln Vivo |
In vivo, Gomisin J has potential benefits in treating nonalcoholic fatty liver disease. Its anti-inflammatory, hepatoprotective, and neuroprotective activities suggest therapeutic potential. However, specific in vivo data are limited.
|
| Enzyme Assay |
In vitro non-cell enzyme assays for Gomisin J involve measuring its inhibition of HIV-1 reverse transcriptase or other viral enzymes. Its metabolism by CYP3A4 can be studied using microsomal preparations and a substrate, measuring the rate of metabolite formation.
|
| Cell Assay |
In vitro cell-based assays for Gomisin J use HIV-infected H9 T cells to assess its antiviral activity. HepG2 cells are used to study its effects on lipid metabolism, where lipid accumulation is measured by Oil Red O staining, and the activation of AMPK is confirmed by western blot.
|
| Animal Protocol |
In vivo animal studies for Gomisin J would employ models of nonalcoholic fatty liver disease or cancer. The compound would be administered to the animals, and parameters such as liver lipid content, tumor growth, and inflammatory markers would be assessed.
|
| ADME/Pharmacokinetics |
Gomisin J has a molecular weight of 388.45 g/mol and a molecular formula of C₂₂H₂₈O₆. It is a lignan with a purity of ≥98%. It is soluble in organic solvents. Detailed pharmacokinetic parameters, such as oral bioavailability, have not been extensively characterized.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Gomisin J has not been fully characterized. As a natural compound, it is generally considered to have low toxicity. However, comprehensive toxicological studies are needed.
|
| References |
|
| Additional Infomation |
Gomisin J is a tannin. It has been reported to be found in Schisandra chinensis, other Schisandra species, and other organisms with relevant data. See also: Schisandra chinensis fruit (partial).
Gomisin J is a bioactive lignan from Schisandra chinensis with diverse activities, including anti-HIV, anti-cancer, anti-inflammatory, and hepatoprotective effects. It activates AMPK and has potential in treating nonalcoholic fatty liver disease. Not approved for clinical use. |
| Molecular Formula |
C22H28O6
|
|---|---|
| Molecular Weight |
388.4541
|
| Exact Mass |
388.188
|
| CAS # |
66280-25-9
|
| PubChem CID |
3001686
|
| Appearance |
White to off-white solid powder
|
| Density |
1.161
|
| Boiling Point |
587.5±50.0 °C at 760 mmHg
|
| Melting Point |
148-149 ºC
|
| Flash Point |
309.1±30.1 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.556
|
| LogP |
4.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
457
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@@H]1CC2=CC(=C(C(=C2C3=C(C(=C(C=C3C[C@@H]1C)O)OC)OC)OC)OC)O
|
| InChi Key |
PICOUNAPKDEPCA-TXEJJXNPSA-N
|
| InChi Code |
InChI=1S/C22H28O6/c1-11-7-13-9-15(23)19(25-3)21(27-5)17(13)18-14(8-12(11)2)10-16(24)20(26-4)22(18)28-6/h9-12,23-24H,7-8H2,1-6H3/t11-,12+
|
| Chemical Name |
(9R,10S)-3,4,15,16-tetramethoxy-9,10-dimethyltricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaene-5,14-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~257.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5743 mL | 12.8717 mL | 25.7433 mL | |
| 5 mM | 0.5149 mL | 2.5743 mL | 5.1487 mL | |
| 10 mM | 0.2574 mL | 1.2872 mL | 2.5743 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
